Aktie A2DU45 DARÉ BIOSCIENCE, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Daré Bioscience, Inc.

Aktien

A2DU45

US23666P1012

DARE

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 01.05.2024 		% 5 Tage % 1. Jan.
0,3299 USD +7,28 % Intraday Chart für Daré Bioscience, Inc. +15,35 % +6,76 %
30.04. Daré Bioscience, Inc. schließt Transaktion zur Monetarisierung von Lizenzgebühren mit XOMA (US) LLC ab CI
30.04. Die XOMA Corporation (NasdaqGM:XOMA) hat die Übernahme von drei First-in-Category Assets von Daré Bioscience, Inc. (NasdaqCM:DARE) für 22 Millionen Dollar abgeschlossen. CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts
Daré Bioscience, Inc. Closes Royalty Monetization Transaction with XOMA (US) LLC
XOMA Corporation completed the acquisition of three First-in-Category Assets of Daré Bioscience, Inc. for $22 million.
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Daré Bioscience, Inc. Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive
Daré Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting
Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
Daré Bioscience, Inc. Announces Positive End-Of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
Daré Bioscience, Inc. Announces Executive Changes
Daré Bioscience, Inc. Announces the Resignation of Lisa Walters-Hoffert as Chief Financial Officer
Dare Bioscience Says Chief Financial Officer Retiring, Chief Commercial Officer Has Resigned
Daré Bioscience Announces Executive Team and Board of Directors Changes
Daré Bioscience Announces Grant to Support Biotherapeutic Product Development
Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases
Daré Bioscience Secures $12 million in Royalty-backed Investment Structure
Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2DU45 Aktie
  4. Nachrichten Daré Bioscience, Inc.
  5. Andere Sprachen